- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT03416907
Informed Consent Formats by Information Preference and Priority
Tutkimuksen yleiskatsaus
Tila
Ehdot
Yksityiskohtainen kuvaus
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskelupaikat
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Yhdysvallat, 15213
- Carnegie Mellon University
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- 18 Years Old or Older
- Read and agreed to informed consent
- Indicated desire to participate
- Diagnosed with asthma
- US resident
Exclusion Criteria:
- Participants from whom we receive multiple responses will be dropped from analysis (but will be compensated for participation)
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Perustiede
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Yksittäinen
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
---|---|
Active Comparator: Original
Participants will review the full-length, original consent form for the clinical trial.
|
Participants will review the full-length, original consent form for the clinical trial.
|
Kokeellinen: Shortened
Participants will review a shortened consent form for the clinical trial, which includes only material indicated as important by 2/3 of participants from a previous study.
|
Participants will review a shortened consent form for the clinical trial, which includes only material indicated as important by 2/3 of participants from a previous study.
|
Kokeellinen: Reordered
Participants will review a reordered, shortened consent form.
This form is based on the shortened consent form, but the sections are reordered based on a previous study, such that sentences previously rated as more likely to impact a participant's decision is more likely to be presented first (except for an initial introductory section).
|
Participants will review a reordered, shortened consent form.
This form is based on the shortened consent form, but the sections are reordered based on a previous study, such that sentences previously rated as more likely to impact a participant's decision is more likely to be presented first (except for an initial introductory section).
|
Kokeellinen: Highlighted
Participants will review a shortened consent form with a highlights box, where the highlights box includes the 10 sentences rates as most likely to impact a participant's decision from a previous study.
|
Participants will review a shortened consent form with a highlights box, where the highlights box includes the 10 sentences rates as most likely to impact a participant's decision from a previous study.
|
Kokeellinen: Interactive
Participants will review an interactive, shortened consent form, where hyperlinks to different sections of the consent form are provided.
The landing page includes the introductory section.
|
Participants will review an interactive, shortened consent form, where hyperlinks to different sections of the consent form are provided.
The landing page includes the introductory section.
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Score for high impact questions
Aikaikkuna: through study completion, an average of 30 minutes
|
Sum of correct answers (T/F) for any item relating to material that was rated as 50 or higher on impact on willingness to enroll in a previous study.
|
through study completion, an average of 30 minutes
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Score for low impact questions
Aikaikkuna: through study completion, an average of 30 minutes
|
Sum of correct answers (T/F) for any item relating to material that was rated as 49 or lower on impact on willingness to enroll in a previous study.
|
through study completion, an average of 30 minutes
|
Total score for all questions
Aikaikkuna: through study completion, an average of 30 minutes
|
Sum of correct answers (T/F) on full knowledge test.
|
through study completion, an average of 30 minutes
|
Interaction effect of format and importance on likelihood of correct answer
Aikaikkuna: through study completion, an average of 30 minutes
|
Interaction effect in a logistic regression predicting a correct answer, based on the format of the consent form and the importance of the answer.
|
through study completion, an average of 30 minutes
|
Scores for different information categories
Aikaikkuna: through study completion, an average of 30 minutes
|
Sum of correct answers (T/F) for each of the 20 information categories
|
through study completion, an average of 30 minutes
|
Effect of location on score
Aikaikkuna: through study completion, an average of 30 minutes
|
Logistic regression coefficient of likelihood of predicting a correct answer, based upon the location on which the sentence appeared--uses only the shortened, and the reordered conditions.
Note that sentences appearing in the introduction (which is the first section of all treatments) must be dropped, as there will be no variation in location.
|
through study completion, an average of 30 minutes
|
Decision to enroll
Aikaikkuna: through study completion, an average of 30 minutes
|
Likert measure of participants hypothetical decision to enroll in the study
|
through study completion, an average of 30 minutes
|
Confidence in enrollment decision
Aikaikkuna: through study completion, an average of 30 minutes
|
Likert measure of participants confidence in hypothetical decision to enroll in the study
|
through study completion, an average of 30 minutes
|
Satisfaction with consent structure
Aikaikkuna: through study completion, an average of 30 minutes
|
Likert measure of participants satisfaction with the consent form
|
through study completion, an average of 30 minutes
|
Perception of investigator concern for well being
Aikaikkuna: through study completion, an average of 30 minutes
|
Likert measure of participants belief in the investigator's concerns for the participant's well-being
|
through study completion, an average of 30 minutes
|
Perception of investigator transparency
Aikaikkuna: through study completion, an average of 30 minutes
|
Likert measure of participants belief that the investigator is trying to communicate information about the trial accurately
|
through study completion, an average of 30 minutes
|
Participant's probability estimate of the likelihood that the treatment would help control their asthma
Aikaikkuna: through study completion, an average of 30 minutes
|
Survey question of the following form: 'If you enrolled in the trial described in the consent form, what is the probability that the treatment could help control your asthma better, where 0% means "no chance at all of helping" and 100% means "would definitely help"?' Participants provided with drop-down menu including values from 0% to 100% in increments of 1%. |
through study completion, an average of 30 minutes
|
Muut tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Participant's free-response text describing what was learned from reading the informed consent document
Aikaikkuna: through study completion, an average of 30 minutes
|
Survey question of the following form: "What are some of the key things you learned from reading the informed consent document?" Participants are then provided with an free-response text box where they are allowed to enter whatever text they want, as long as they enter some text. These responses will be coded by two independent coders, blinded to the treatment arms, using an emergent coding system to identify different topics that participants may raise. |
through study completion, an average of 30 minutes
|
Yhteistyökumppanit ja tutkijat
Sponsori
Yhteistyökumppanit
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muut tutkimustunnusnumerot
- STUDY2017_00000268
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Original consent form
-
University of PennsylvaniaValmisKriittinen sairausYhdysvallat
-
Jules Bordet InstituteRoche Pharma AGLopetettu
-
Bio-Strath AGZentrum für Adipositas- und Stoffwechselmedizin Winterthur GmbHTuntematon
-
Ottawa Hospital Research InstituteRekrytointiTyypin 2 diabetesKanada
-
Mike O'Callaghan Military HospitalValmis
-
Mike O'Callaghan Military HospitalValmis
-
Mayo ClinicValmisVakavasti sairasYhdysvallat
-
Tahitian Noni International, Inc.University of Illinois at ChicagoValmis
-
TakedaBaxter Healthcare CorporationValmis